GlassScriptPhysician profile
Bruce L Newman
NPI 1154502862
$7,852.53
in general payments reported to CMS, 2019-2025
29 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,420 · 2020: $844 · 2021: $584 · 2022: $1,398 · 2023: $941 · 2024: $1,166 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,607.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $848.78 | 2025 | M22 |
| Alcon Vision LLC | $804.66 | 2021-2025 | Clareon, Unity, Clareon Panoptix Pro |
| Bausch & Lomb Americas INC. | $684.18 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $611.00 | 2019-2021 | |
| Notal Vision, INC. | $590.30 | 2022 | |
| Glaukos Corporation | $575.39 | 2019-2025 | Idosetr |
| Novartis Pharmaceuticals Corporation | $574.44 | 2019-2020 | |
| Allergan, INC. | $404.54 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $317.80 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $313.23 | 2019-2024 | |
| Rxsight INC | $280.39 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Tarsus Pharmaceuticals, INC. | $273.49 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $222.85 | 2019-2020 | |
| Oyster Point Pharma, INC. | $191.01 | 2023-2024 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $183.95 | 2021-2024 | Tecnis Simplicity |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $144.21 | 2024-2025 | Oxervate |
| Eyepoint US, INC. | $124.10 | 2021 | |
| Ivantis, INC | $108.68 | 2019 | |
| Lombart Brothers, INC. | $101.06 | 2023 | Opd-III |
| Biotissue Holdings INC. | $97.12 | 2022 | |
| Genentech USA, INC. | $81.04 | 2022 | |
| Amgen INC. | $80.01 | 2024 | Tepezza |
| Mallinckrodt Hospital Products INC. | $61.24 | 2022-2024 | Acthar |
| Carl Zeiss Meditec, INC. | $57.55 | 2019 | |
| Ocular Therapeutix, INC. | $34.78 | 2019-2023 | Dextenza |
| Galderma Laboratories, L.P. | $27.59 | 2019-2022 | |
| New World Medical,INC. | $24.22 | 2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Abbvie INC. | $17.81 | 2024 | |
| Eyevance Pharmaceuticals LLC | $17.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.